Glycemic control was slightly better with lixisenatide: mean postbaseline difference, -0.27% (95% CI: -0.32 to -0.22)
Shallow enough that pinpoint bleeding is uncommon and recovery is minimal
Next-generation candidates like Novos CagriSema or Amgens MariTide will need to demonstrate meaningful advantages in cardiovascular outcomes, NASH or metabolic disease to command better pricing
(2021c)
Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Mlarstig A, Brismar K, Hamsten A, Fisher RM, Hellnius M-L
However, it is always best to consult with your healthcare provider to determine the right schedule for your specific needs, especially if you have existing health concerns